# EDGAR Filing Document

**Accession Number:** 0000031791
**File Stem:** 0001157523-23-000033
**Filing Date:** 2023-1
**Character Count:** 9368
**Document Hash:** 45a3031be9a83b0e9e02c71406a48a61
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001157523-23-000033.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001157523-23-000033

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERKINELMER INC
- **CENTRAL INDEX KEY:** 0000031791
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 042052042
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1229

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05075
- **FILM NUMBER:** 23518268

**BUSINESS ADDRESS:**
- **STREET 1:** 940 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 781-663-5791

**MAIL ADDRESS:**
- **STREET 1:** 940 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EG&G INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EDGERTON GERMESHAUSEN & GRIER INC
- **DATE OF NAME CHANGE:** 19670626

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 9, 2023

------

### PerkinElmer, Inc.

#### (Exact Name of Registrant as Specified in its Charter)

------

---

| | | |
|:---|:---|:---|
| **Massachusetts**<br>| **001-05075**<br>| **04-2052042**<br>|
| **(State or Other Jurisdiction**<br> **of Incorporation or Organization)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **940 Winter Street, Waltham, Massachusetts** | **02451**<br>|
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (781) 663-6900

#### Not applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
| **Common stock, $1 par value per share<br>**  | **PKI<br>**  | **The New York Stock Exchange<br>**  |
| **1.875% Notes due 2026<br>**  | **PKI 21A<br>**  | **The New York Stock Exchange<br>**  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 2.02. Results of Operations and Financial Condition.
On January 9, 2023, PerkinElmer, Inc. (the "Company") announced preliminary expectations with respect to certain financial results for the fourth quarter ended January 1, 2023 and announced that the Company will release its fourth quarter and full year 2022 financial results on February 14, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### Item 9.01. Financial Statements and Exhibits.
(d)&nbsp;&nbsp;&nbsp;&nbsp; Exhibits

---

| | |
|:---|:---|
|  | **EXHIBIT INDEX** |
| **Exhibit No.** | **Description** |
| [99.1](a53183137ex99_1.htm)\* | [Press Release entitled "PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook", issued by PerkinElmer, Inc. on January 9, 2023.](a53183137ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) |

---

\* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PERKINELMER, INC. | PERKINELMER, INC. |
| Date: January 9, 2023 | By: | /s/ Joel S. Goldberg |
|  |  | Joel S. Goldberg |
|  |  | Senior Vice President, Administration, General Counsel and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**<br>

**** 

<br> # **PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook** 
WALTHAM, Mass.--(BUSINESS WIRE)--January 9, 2023--PerkinElmer Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

To access the call, a live audio webcast will be available via this registration formor on the Investorssection of the Company's website.

The Company is also updating its fourth quarter 2022 guidance as previously provided on November 8, 2022. The Company now expects its fourth quarter 2022 results to meet or exceed the guidance provided on November 8, 2022.

 **Factors Affecting Future Performance**

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future adjusted earnings per share, revenue, revenue growth and other financial results. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates", "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: the completion of quarterly and year end closing procedures for the fourth quarter and fiscal year ended January 1, 2023 and other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

 **About PerkinElmer**

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of more than 16,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram and YouTube.

## Contacts
 **Investor Relations:** <br> Steve Willoughby <br> (781) 663-5677 <br> steve.willoughby@perkinelmer.com

 **Media Relations:** <br> Chet Murray <br> (781) 663-5719 <br> chet.murray@perkinelmer.com